On December 12, 2023, upon mutual agreement between CorMedix Inc. (the ?Company?) and Phoebe Mounts, Ph.D., Esq., the Company?s Executive Vice President, General Counsel and Corporate Secretary, the Board of Directors of the Company (the ?Board?) approved the separation of employment of Dr. Mounts, effective December 31, 2023 (the ?Termination Date?). Dr. Mounts will cease to hold the title of General Counsel and Corporate Secretary effective December 12, 2023. Until the Termination Date, Dr. Mounts will continue to serve as Executive Vice President and devote her time and attention to facilitating the transition of her duties and responsibilities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.31 USD | +2.31% | +0.57% | +41.22% |
Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.22% | 292M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- CorMedix Inc. Approves the Separation of Employment of Phoebe Mounts